Completed PHASE3 INTERVENTIONAL 2-arm NCT01506882

An Open Label Study of Levetiracetam Monotherapy in Patients With Newly Diagnosed Focal Epilepsy

An Open-label, Randomized, Multicenter Study to Evaluate the Efficacy and Safety of Levetiracetam Used as Monotherapy in Newly or Recently Diagnosed Epilepsy Patients Aged Older Than or Equal to 16 Years With Partial Seizures

Sponsor: UCB Japan Co. Ltd.

Conditions Epilepsy Partial Onset Seizures

Interventions Levetiracetam (LEV)

Updated 7 times since 2017 Last updated: Nov 24, 2015 Started: Dec 31, 2011 Primary completion: Oct 31, 2013 Completion: Apr 30, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Epilepsy and Partial Onset Seizures and is currently completed. UCB Japan Co. Ltd. leads this study, which shows 7 recorded versions since 2011 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE3
Jan 2017 — Feb 2017 [monthly]

Completed PHASE3

First recorded

Dec 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

UCB Japan Co. Ltd.

Data source: UCB Pharma

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aomori, Japan , Asaka, Japan , Daitō, Japan , Fujisawa, Japan , Hamamatsu, Japan , Himeji, Japan , Hirosaki, Japan , Kagoshima, Japan , Kamakura, Japan , Kawasaki, Japan and 16 more locations